Our pan-cancer analyses from TCGA revealed that aberrant expressions of ELF3, EHF, and TGIF1 are prevalent in a wide spectrum of cancers (Fig. S4A–C) and high levels of these master TFs are associated with poor patient outcomes (Fig. 2D). The gene discussed is EHF; the disease is cancer.